Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease
Status:
Completed
Trial end date:
2019-07-22
Target enrollment:
Participant gender:
Summary
This study is to characterize the safety and tolerability of an investigational drug called
TIMP-GLIA when either one or two intravenous doses are given to subjects with celiac disease.
The way the body reacts to TIMP-GLIA is being checked by laboratory tests of the blood and
urine, and study subject health will also be monitored by vital signs such as blood pressure,
electrocardiogram (ECG), and physical examination.
Phase:
Phase 1
Details
Lead Sponsor:
Cour Pharmaceutical Development Company, Inc. Takeda